Ifosfamide with mesna uroprotection in the management of lung cancer.

Holoye, P Y; Glisson, B S; Lee, J S; Dhingra, H M; Murphy, W K; Umsawasdi, T; Levy, J K; Jeffries, D; Raber, M N; Hong, W K

Holoye, P Y; Glisson, B S; Lee, J S; Dhingra, H M; Murphy, W K; Umsawasdi, T; Levy, J K; Jeffries, D; Raber, M N; Hong, W K.

Affiliation

Holoye PY; Department of Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030.

Am J Clin Oncol ; 13(2): 148-55, 1990 Apr.

Article in En | MEDLINE | ID: mdl-2156418

Subject(s)

Carcinoma, Bronchogenic/drug therapy; Ifosfamide/therapeutic use; Lung Neoplasms/drug therapy; Mercaptoethanol/analogs & derivatives; Mesna/therapeutic use; Urologic Diseases/prevention & control; Aged; Carcinoma, Non-Small-Cell Lung/drug therapy; Carcinoma, Small Cell/drug therapy; Female; Humans; Ifosfamide/adverse effects; Lung Neoplasms/mortality; Male; Middle Aged; Survival Rate; Urologic Diseases/chemically induced; Vincristine/administration & dosage

Search on Google

XML

PubMed Links

Database: MEDLINE Main subject: Urologic Diseases / Carcinoma, Bronchogenic / Mesna / Ifosfamide / Lung Neoplasms / Mercaptoethanol Limits: Aged / Female / Humans / Male / Middle aged Language: En Year: 1990 Type: Article

Search on Google

XML

PubMed Links